Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dara-VCd vs VTd in Newly Diagnosed Multiple Myeloma Eligible for ASCT
NCT03896737Phase 2Active, not recruiting
- Start
- Apr 2019
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of daratumumab in multiple myeloma (MM) (2 arms). Primary endpoints: Progression Free Survival at 5 years and Minimal Residual Disease negativity at 5 years. Started Apr 2019; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03896737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896737.